æ€çŽ¢
- eol
çåœç¶ææ²»çã®å·®ãæ§ãã»äžæ¢ã«é¢ããæ³å¶åºŠã®4ã«åœæ¯èŒ(æ¥æ¬ãå°æ¹Ÿãéåœãè±åœ)ã®è«æãBMC Medical Ethicsã«æ²èŒãããŸãã
æŽæ°æ¥ïŒ2023幎11æ1æ¥
æ¬ãããžã§ã¯ãã®ã¡ã³ããŒïŒç°äžçŸç©ãå çè¡ãIlhak LeeãéŸå®éïŒãšRichard Huxtableææã«ããçåœç¶ææ²»çã®å·®ãæ§ãã»äžæ¢ã«é¢ããæ³å¶åºŠã®4ã«åœæ¯èŒ(æ¥æ¬ãå°æ¹Ÿãéåœãè±åœ)ã®è«æãBMC Medical Ethicsã«æ²èŒãããŸããã
Tanaka, M. et al. (2020) âForgoing life-sustaining treatment â a comparative analysis of regulations in Japan, Korea, Taiwan, and Englandâ. BMC Medical Ethics, 21(1), pp. 1â15. doi: 10.1186/s12910-020-00535-w.
ãé¢å¿ã®ããæ¹ã¯äžèšãªã³ã¯ããã芧ãã ããã